Chemistry and Engineering Technology Center, PharmaBlock, Zhejiang
PharmaBlock Sciences (Nanjing), Inc. has opened a new Chemistry and Engineering Technology Center (CETC), the company announced on April 15.
Chemistry and Engineering Technology Center (CETC) Location
The new Chemistry and Engineering Technology Center (CETC) is located next to the PharmaBlock GMP manufacturing plant in Shangyu, Zhejiang Province, China. Covering an area of 32,300 ft2, the ultra-modern Zhejiang CETC was constructed with an investment of approximately 8 million USD.
The introduction of the new CETC would further enhance the chemistry and engineering technology network of PharmaBlock, while supporting a greener, safer and more efficient chemistry process and production capability.
PharmaBlock’s CETC technology
Featuring cutting edge equipment and experienced chemists and engineers, the Chemistry and Engineering Technology Center is dedicated to delivering innovative solutions with a focus on flow chemistry, micropacked bed reaction, biocatalysis, and an a wide spectrum of engineering technologies, including but not limited to separation, crystallization, and application of Distributed Control System (DCS) and process simulation.
Dr. Minmin Yang, Founder & Chairman of PharmaBlock stated:
“Today, increased pressure for green, safe and sustainable supply chain management within the pharmaceutical industry has given rise to innovative chemistry and engineering technologies. We consider innovative technologies a fundamental part and cornerstone of PharmaBlock’s current and future success, and as a key component of our overall innovation strategy, the CETC will definitely consolidate our competitiveness.”
Application of Micropacked Bed Technology in Continuous Manufacturing
Amongst the new technologies integrated by PharmaBlock, the highlight is the application of micropacked bed technology in flow hydrogenation. This niche problem-solving micropacked bed technology, which has been increasingly adopted in the pharmaceutical industry, is not only applied in lab scale, but also in pilot and manufacturing scale at PharmaBlock, with a daily output of 100Kg to 1000Kg.
Dr. Yuanping Jie, Head of CETC added:
“Micropacked beds have been successfully applied to the development and manufacturing of several dozen of our projects. We have seen many superiorities micropacked bed creates over conventional methods: lower safety risk, lower wastes, cost and space saving, consistent quality, and robust process with simple control.”
“In addition to the existing 5L and 10L micropacked bed reactors designed by our in-house engineering team, the CETC will add more scale-up equipment, expand the application into more reaction types, like oxidation, and enhance the automated mode to further ensure safety and high efficiency.”
Benefits of the new Zhejiang CETC
PharmaBlock’s customers will benefit from the addition of the CETC in many ways, the company stated in their press release. Most importantly, by being located next to the Zhejiang GMP site, the new CETC will support more innovative solutions to help overcome scale-up challenges in customers’ projects, resulting in shortened lead times and overall cost savings. The CETC also takes responsibility to optimise the scaling up process of PharmaBlock’s building blocks, which could be broadly used in many drug development and clinical drug manufacturing settings.
Latest Projects
- Merck KGaA Invests € 300m for New Research Centre in Darmstadt, Germany
Merck KGaA (Merck) announced an investment today of more than €300 Million ($320.8m) in a new Life Science Research Centre - Production Facilities Expansion, Novo Nordisk, Chartres, France
Novo Nordisk, a global pharmaceutical leader, has set in motion an extensive expansion project for its production facility in Chartres, - Manufacturing Pharmaceuticals In Space
Varda Space Industries, a California-based startup, is venturing into the realm of pharmaceutical manufacturing in microgravity with the goal of - Plasma-Derived Therapies Manufacturing Plant, 2030, Takeda, Osaka, Japan
Takeda plans to invest approximately 100 Billion Yen ( 762,330,000 Million USD) to construct a new manufacturing plant for plasma-derived - Continuous Manufacturing Line for Oral Solids, WuXi STA, China
WuXi STA, a subsidiary of WuXi AppTec, opened the doors of its first pharmaceutical product Continuous Manufacturing (CM) line for - BioNTech Boosts Autonomy with In-House Plasmid DNA Manufacturing Facility in Marburg
The construction of BioNTech’s first in-house plasmid DNA processing plant in Marburg, Germany, has now been completed, the company announced
